The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: A double-blind, dose-finding, placebo-controlled study

2000 ◽  
Vol 182 (3) ◽  
pp. 575-581 ◽  
Author(s):  
Catharina A.H. Janssen ◽  
Piet C. Scholten ◽  
A.Peter M. Heintz
Keyword(s):  
Blood Loss ◽  
Low Dose ◽  
Dose Finding ◽  
Intrauterine Contraceptive Device ◽  
Menstrual Blood ◽  
Controlled Study ◽  
Contraceptive Device ◽  
Menstrual Blood Loss ◽  
Double Blind ◽  
Intrauterine Contraceptive

The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status

Contraception ◽  
1992 ◽  
Vol 46 (4) ◽  
pp. 327-334 ◽  
Author(s):  
Gerd Larsson ◽  
Lan Milsom ◽  
Göran Lindstedt ◽  
Göran Rybo
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Low Dose ◽  
Iron Status ◽  
Menstrual Blood ◽  
Menstrual Blood Loss ◽  
Combined Oral Contraceptive

Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo

1987 ◽  
Vol 65 (10) ◽  
pp. 2081-2084 ◽  
Author(s):  
B. K. Tsang ◽  
M. T. Domingo ◽  
J. E. H. Spence ◽  
P. R. Garner ◽  
D. K. Dudley ◽  
...  
Keyword(s):  
Blood Loss ◽  
Mefenamic Acid ◽  
Menstrual Blood ◽  
Etiologic Factor ◽  
Prostaglandin E ◽  
Menstrual Blood Loss ◽  
Prostaglandin Synthetase ◽  
Double Blind ◽  
Prostaglandin F

Prostaglandin levels in the human endometrium were determined on day 2 of the menstrual cycle in eumenorrheic subjects and in patients with menorrhagia, dysmenorrhea, or both. Menorrhagic subjects had significantly higher levels of endometrial prostaglandins of the E and F series when compared with eumenorrheics. Prostaglandin E levels were markedly higher than prostaglandin F. In 10 menorrhagic subjects who completed a double-blind clinical study on the effectiveness of mefenamic acid in lowering menstrual blood loss, 9 exhibited statistically significant reduction in endometrial prostaglandin levels. A decrease in menstrual blood loss was also noted during mefenamic acid treatment in these patients. These findings are consistent with the concept that abnormally high uterine prostaglandin levels may be an important etiologic factor in menorrhagia and support the notion that one of the mechanisms of action of nonsteroidal anti-inflammatory agents in the treatment of this menstrual disorder is inhibition of endometrial prostaglandin production.

Sign in / Sign up

Export Citation Format

Share Document